Abstract
Nucleolin (NCL) is one of several potential molecular biomarkers that have been suggested as predictors for pediatric intracranial ependymomas. However, few studies have assessed whether NCL is an optimal prognostic marker to predict outcome in pediatric intracranial ependymoma. Thus, this systematic review and meta-analysis aimed to examine the prognostic role of NCL in predicting the outcome of patients with intracranial ependymoma.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
